A comparison of lithium and T3 augmentation following two failed medication treatments for depression: A STAR*D report

Andrew A. Nierenberg, Maurizio Fava, Madhukar H. Trivedi, Stephen R. Wisniewski, Michael E. Thase, Patrick J. McGrath, Jonathan E. Alpert, Diane Warden, James F. Luther, George Niederehe, Barry Lebowitz, Kathy Shores-Wilson, A. John Rush

Research output: Contribution to journalArticle

299 Citations (Scopus)

Abstract

Objective: More than 40% of patients with major depressive disorder do not achieve remission even after two optimally delivered trials of antidepressant medications. This study compared the effectiveness of lithium versus triiodothyronine (T3) augmentation as a third-step treatment for patients with major depressive disorder. Method: A total of 142 adult outpatients with nonpsychotic major depressive disorder who had not achieved remission or who were intolerant to an initial prospective treatment with citalopram and a second switch or augmentation trial were randomly assigned to augmentation with lithium (up to 900 mg/day; N=69) or with T3 (up to 50 μg/day; N=73) for up to 14 weeks. The primary outcome measure was whether participants achieved remission, which was defined as a score ≤7 on the 17-item Hamilton Depression Rating Scale. Results: After a mean of 9.6 weeks (SD=5.2) of treatment, remission rates were 15.9% with lithium augmentation and 24.7% with T3 augmentation, although the difference between treatments was not statistically significant. Lithium was more frequently associated with side effects (p=0.045), and more participants in the lithium group left treatment because of side effects (23.2% versus 9.6%; p=0.027). Conclusions: Remission rates with lithium and T3 augmentation for participants who experienced unsatisfactory results with two prior medication treatments were modest and did not differ significantly. The lower side effect burden and ease of use of T3 augmentation suggest that it has slight advantages over lithium augmentation for depressed patients who have experienced several failed medication trials.

Original languageEnglish (US)
Pages (from-to)1519-1530
Number of pages12
JournalAmerican Journal of Psychiatry
Volume163
Issue number9
DOIs
StatePublished - Sep 2006
Externally publishedYes

Fingerprint

Lithium
Depression
Major Depressive Disorder
Therapeutics
Citalopram
Triiodothyronine
Antidepressive Agents
Outpatients
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Nierenberg, A. A., Fava, M., Trivedi, M. H., Wisniewski, S. R., Thase, M. E., McGrath, P. J., ... Rush, A. J. (2006). A comparison of lithium and T3 augmentation following two failed medication treatments for depression: A STAR*D report. American Journal of Psychiatry, 163(9), 1519-1530. https://doi.org/10.1176/appi.ajp.163.9.1519

A comparison of lithium and T3 augmentation following two failed medication treatments for depression : A STAR*D report. / Nierenberg, Andrew A.; Fava, Maurizio; Trivedi, Madhukar H.; Wisniewski, Stephen R.; Thase, Michael E.; McGrath, Patrick J.; Alpert, Jonathan E.; Warden, Diane; Luther, James F.; Niederehe, George; Lebowitz, Barry; Shores-Wilson, Kathy; Rush, A. John.

In: American Journal of Psychiatry, Vol. 163, No. 9, 09.2006, p. 1519-1530.

Research output: Contribution to journalArticle

Nierenberg, AA, Fava, M, Trivedi, MH, Wisniewski, SR, Thase, ME, McGrath, PJ, Alpert, JE, Warden, D, Luther, JF, Niederehe, G, Lebowitz, B, Shores-Wilson, K & Rush, AJ 2006, 'A comparison of lithium and T3 augmentation following two failed medication treatments for depression: A STAR*D report', American Journal of Psychiatry, vol. 163, no. 9, pp. 1519-1530. https://doi.org/10.1176/appi.ajp.163.9.1519
Nierenberg, Andrew A. ; Fava, Maurizio ; Trivedi, Madhukar H. ; Wisniewski, Stephen R. ; Thase, Michael E. ; McGrath, Patrick J. ; Alpert, Jonathan E. ; Warden, Diane ; Luther, James F. ; Niederehe, George ; Lebowitz, Barry ; Shores-Wilson, Kathy ; Rush, A. John. / A comparison of lithium and T3 augmentation following two failed medication treatments for depression : A STAR*D report. In: American Journal of Psychiatry. 2006 ; Vol. 163, No. 9. pp. 1519-1530.
@article{82f72cdf26f74bf1a280b074e0e2b5ad,
title = "A comparison of lithium and T3 augmentation following two failed medication treatments for depression: A STAR*D report",
abstract = "Objective: More than 40{\%} of patients with major depressive disorder do not achieve remission even after two optimally delivered trials of antidepressant medications. This study compared the effectiveness of lithium versus triiodothyronine (T3) augmentation as a third-step treatment for patients with major depressive disorder. Method: A total of 142 adult outpatients with nonpsychotic major depressive disorder who had not achieved remission or who were intolerant to an initial prospective treatment with citalopram and a second switch or augmentation trial were randomly assigned to augmentation with lithium (up to 900 mg/day; N=69) or with T3 (up to 50 μg/day; N=73) for up to 14 weeks. The primary outcome measure was whether participants achieved remission, which was defined as a score ≤7 on the 17-item Hamilton Depression Rating Scale. Results: After a mean of 9.6 weeks (SD=5.2) of treatment, remission rates were 15.9{\%} with lithium augmentation and 24.7{\%} with T3 augmentation, although the difference between treatments was not statistically significant. Lithium was more frequently associated with side effects (p=0.045), and more participants in the lithium group left treatment because of side effects (23.2{\%} versus 9.6{\%}; p=0.027). Conclusions: Remission rates with lithium and T3 augmentation for participants who experienced unsatisfactory results with two prior medication treatments were modest and did not differ significantly. The lower side effect burden and ease of use of T3 augmentation suggest that it has slight advantages over lithium augmentation for depressed patients who have experienced several failed medication trials.",
author = "Nierenberg, {Andrew A.} and Maurizio Fava and Trivedi, {Madhukar H.} and Wisniewski, {Stephen R.} and Thase, {Michael E.} and McGrath, {Patrick J.} and Alpert, {Jonathan E.} and Diane Warden and Luther, {James F.} and George Niederehe and Barry Lebowitz and Kathy Shores-Wilson and Rush, {A. John}",
year = "2006",
month = "9",
doi = "10.1176/appi.ajp.163.9.1519",
language = "English (US)",
volume = "163",
pages = "1519--1530",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "9",

}

TY - JOUR

T1 - A comparison of lithium and T3 augmentation following two failed medication treatments for depression

T2 - A STAR*D report

AU - Nierenberg, Andrew A.

AU - Fava, Maurizio

AU - Trivedi, Madhukar H.

AU - Wisniewski, Stephen R.

AU - Thase, Michael E.

AU - McGrath, Patrick J.

AU - Alpert, Jonathan E.

AU - Warden, Diane

AU - Luther, James F.

AU - Niederehe, George

AU - Lebowitz, Barry

AU - Shores-Wilson, Kathy

AU - Rush, A. John

PY - 2006/9

Y1 - 2006/9

N2 - Objective: More than 40% of patients with major depressive disorder do not achieve remission even after two optimally delivered trials of antidepressant medications. This study compared the effectiveness of lithium versus triiodothyronine (T3) augmentation as a third-step treatment for patients with major depressive disorder. Method: A total of 142 adult outpatients with nonpsychotic major depressive disorder who had not achieved remission or who were intolerant to an initial prospective treatment with citalopram and a second switch or augmentation trial were randomly assigned to augmentation with lithium (up to 900 mg/day; N=69) or with T3 (up to 50 μg/day; N=73) for up to 14 weeks. The primary outcome measure was whether participants achieved remission, which was defined as a score ≤7 on the 17-item Hamilton Depression Rating Scale. Results: After a mean of 9.6 weeks (SD=5.2) of treatment, remission rates were 15.9% with lithium augmentation and 24.7% with T3 augmentation, although the difference between treatments was not statistically significant. Lithium was more frequently associated with side effects (p=0.045), and more participants in the lithium group left treatment because of side effects (23.2% versus 9.6%; p=0.027). Conclusions: Remission rates with lithium and T3 augmentation for participants who experienced unsatisfactory results with two prior medication treatments were modest and did not differ significantly. The lower side effect burden and ease of use of T3 augmentation suggest that it has slight advantages over lithium augmentation for depressed patients who have experienced several failed medication trials.

AB - Objective: More than 40% of patients with major depressive disorder do not achieve remission even after two optimally delivered trials of antidepressant medications. This study compared the effectiveness of lithium versus triiodothyronine (T3) augmentation as a third-step treatment for patients with major depressive disorder. Method: A total of 142 adult outpatients with nonpsychotic major depressive disorder who had not achieved remission or who were intolerant to an initial prospective treatment with citalopram and a second switch or augmentation trial were randomly assigned to augmentation with lithium (up to 900 mg/day; N=69) or with T3 (up to 50 μg/day; N=73) for up to 14 weeks. The primary outcome measure was whether participants achieved remission, which was defined as a score ≤7 on the 17-item Hamilton Depression Rating Scale. Results: After a mean of 9.6 weeks (SD=5.2) of treatment, remission rates were 15.9% with lithium augmentation and 24.7% with T3 augmentation, although the difference between treatments was not statistically significant. Lithium was more frequently associated with side effects (p=0.045), and more participants in the lithium group left treatment because of side effects (23.2% versus 9.6%; p=0.027). Conclusions: Remission rates with lithium and T3 augmentation for participants who experienced unsatisfactory results with two prior medication treatments were modest and did not differ significantly. The lower side effect burden and ease of use of T3 augmentation suggest that it has slight advantages over lithium augmentation for depressed patients who have experienced several failed medication trials.

UR - http://www.scopus.com/inward/record.url?scp=33749049165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749049165&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.163.9.1519

DO - 10.1176/appi.ajp.163.9.1519

M3 - Article

C2 - 16946176

AN - SCOPUS:33749049165

VL - 163

SP - 1519

EP - 1530

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 9

ER -